Pharmacokinetics of 99mTc-techephore in man

Assessment of the pharmacokinetics of 99mTc-technephore in the human body was based on a analysis of the results of its study in 43 out of 87 patients with neoplasms of nonosteogenic origin (breast cancer, lung cancer, reticulum cell sarcome, etc.) Radiometry by means of a counter of the whole human body radiation was performed shortly after the drug administration with one-hour intervals for 4-5 hours. Methods of blood radiometry and osteoscintigraphy were employed. The study showed that the redistribution of the drug occured in the first minutes after its injection, chiefly between in the 2 volumes: the skeleton and the urinary system. Investigations of the patients with the help of gamma-chambers and scanners were initiated 2.5-3 hours after the drug injection. The sensitivity and specificity of 99mTc-technephore were similar to thoe of other phosphatic and phosphonate radiopharmaceuticals: 96 and 12%. A conclusion was made that the drug could be used in clinical practice as an osteotropic agent